Eos Focused Equity Management buys $8,213,149 stake in NuVasive (NUVA)

NuVasive (NUVA) : Eos Focused Equity Management scooped up 9,515 additional shares in NuVasive during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 9, 2016. The investment management firm now holds a total of 154,615 shares of NuVasive which is valued at $8,213,149.NuVasive makes up approximately 7.64% of Eos Focused Equity Management’s portfolio.

Other Hedge Funds, Including , Puplava Financial Services reduced its stake in NUVA by selling 10,386 shares or 35.62% in the most recent quarter. The Hedge Fund company now holds 18,771 shares of NUVA which is valued at $997,116. NuVasive makes up approx 0.61% of Puplava Financial Services’s portfolio. Ausdal Financial Partners sold out all of its stake in NUVA during the most recent quarter. The investment firm sold 1,200 shares of NUVA which is valued $63,168. Ramsey Quantitative Systems added NUVA to its portfolio by purchasing 11,723 company shares during the most recent quarter which is valued at $617,099. NuVasive makes up approx 0.64% of Ramsey Quantitative Systems’s portfolio.Curian Capital reduced its stake in NUVA by selling 10,466 shares or 61.58% in the most recent quarter. The Hedge Fund company now holds 6,529 shares of NUVA which is valued at $345,645. NuVasive makes up approx 0.03% of Curian Capital’s portfolio.Louisiana State Employees Retirement System boosted its stake in NUVA in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 22,000 shares of NuVasive which is valued at $1,164,680. NuVasive makes up approx 0.06% of Louisiana State Employees Retirement System’s portfolio.

NuVasive opened for trading at $52.14 and hit $53.18 on the upside on Friday, eventually ending the session at $53.12, with a gain of 0.99% or 0.52 points. The heightened volatility saw the trading volume jump to 7,56,867 shares. Company has a market cap of $2,647 M.

On the company’s financial health, NuVasive reported $0.31 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.27. The company had revenue of $215.10 million for the quarter, compared to analysts expectations of $205.44 million. The company’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS.

Nuvasive Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Company’s software-driven nerve detection and avoidance systems including NVM5 and NVJJB Intra-Operative Monitoring (IOM) services and support; MaXcess which is an integrated split-blade retractor system and a variety of implants and biologics.

Leave a Reply

NuVasive - Is it time to Sell?

Top Brokerage Firms are advising their investors on NuVasive. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.